Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

NCT01531998 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Myeloma

Interventions

DRUG: Lenalidomide
DRUG: Bortezomib
DRUG: Siltuximab
DRUG: Dexamethasone
BEHAVIORAL: Questionnaires

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]